Article Information
Accepted for Publication: December 6, 2021.
Published: February 14, 2022. doi:10.1001/jamanetworkopen.2021.48355
Open Access: This is an open access article distributed under the terms of the
CC-BY License. © 2022 Zissimopoulos J et al.
JAMA Network Open.
Corresponding Author: Julie Zissimopoulos, PhD, Associate Professor, Department of Health Policy and Management,
Sol Price School of Public Policy, University of Southern California, 635 Downey Way,
Verna and Peter Dauterive Hall, Los Angeles, CA 90089 (
zissimop@
123456usc.edu
).
Author Contributions: Dr Zissimopoulos had full access to all of the data in the study and takes responsibility
for the integrity of the data and the accuracy of the data analysis.
Concept and design: Zissimopoulos, Jacobson, Borson.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Zissimopoulos, Chen.
Critical revision of the manuscript for important intellectual content: Zissimopoulos, Jacobson, Borson.
Statistical analysis: Zissimopoulos, Chen.
Obtained funding: Zissimopoulos.
Administrative, technical, or material support: Jacobson.
Supervision: Zissimopoulos.
Background on aducanumab approval, Food and Drug Administration process, Alzheimer
disease outcomes:
Borson.
Conflict of Interest Disclosures: Dr Borson reported serving as an author of an information sheet prepared by the American
Geriatrics Society for consumers and patients regarding aducanumab. No other disclosures
were reported.
Funding/Support: This work was funded by grants P30AG066589, P30AG043073, and R01AG055401 from the
National Institutes of Health.
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management,
analysis, and interpretation of the data; preparation, review, or approval of the
manuscript; and decision to submit the manuscript for publication.